Skip to main content

Advertisement

SpringerLink
Log in

Biochemical modulation of fluorouracil in patients with metastatic colorectal cancer

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Conclusions

Eniluracil with 5-FU administered orally with or without leucovorin on a 5-day schedule appears to be active and well-tolerated when given as primary therapy to patients with untreated metastatic colorectal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Ronald M. Bukowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukowski, R.M. Biochemical modulation of fluorouracil in patients with metastatic colorectal cancer. Curr Oncol Rep 3, 130 (2001). https://doi.org/10.1007/s11912-001-0012-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0012-9

Keywords

Search

Navigation